optimized background therapy

DRUG2 trials

Sponsors

ViiV Healthcare

Conditions

HIV Infections

Phase 2

Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects

CompletedNCT00098306

ViiV HealthcareHIV Infections

Start: 2004-11-30End: 2011-04-30Updated: 2012-04-27

Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects

CompletedNCT00098722

ViiV HealthcareHIV Infections

Start: 2004-12-31End: 2011-04-30Updated: 2012-05-16

Related Papers

V3-Loop genotypes do not predict maraviroc susceptibility of CCR5-tropic virus or clinical response through week 48 in HIV-1–infected, treatment-experienced persons receiving optimized background regimens

Antiviral chemistry & chemotherapy2021-01-013 citations

Incidence of CXCR4 tropism and CCR5-tropic resistance in treatment-experienced participants receiving maraviroc in the 48-week MOTIVATE 1 and 2 trials

Antiviral chemistry & chemotherapy2019-01-015 citations

Maraviroc for previously treated patients with R5 HIV-1 infection.

2008-10-01536 citations

Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection.

2008-10-01249 citations